Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
This study is ongoing, but not recruiting participants.
Study NCT00077116
Information provided by National Cancer Institute (NCI)
First Received: February 10, 2004
Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
